Sundowning syndrome in aging and dementia: Research in mouse models

Experimental Neurology

Volumn 243, Issue , 2013, Pages 67-73

  Bedrosian, Tracy A ^a   Nelson, Randy J ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Aging; Agitation; Alzheimer disease; Circadian

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; DONEPEZIL; MELATONIN; SCOPOLAMINE;

AGING; AGITATION; AROUSAL; BEHAVIOR DISORDER; CIRCADIAN RHYTHM; CLINICAL RESEARCH; COST OF ILLNESS; DEMENTIA; DISEASE MODEL; DISEASE SEVERITY; EVIDENCE BASED MEDICINE; HUMAN; MENTAL STRESS; MEYNERT BASAL NUCLEUS; NONHUMAN; PATHOPHYSIOLOGY; PHOTOTHERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SLEEP DISORDER; SUNDOWNING SYNDROME; SUPRACHIASMATIC NUCLEUS; TRANSGENIC MOUSE;

AGING; ANIMALS; CIRCADIAN RHYTHM; CONFUSION; DEMENTIA; DISEASE MODELS, ANIMAL; HUMANS; MICE;

EID: 84875381499     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2012.05.005     Document Type: Review

References (79)

1. Ancoli-Israel S., Kripke D.F. Now I lay me down to sleep: the problem of sleep fragmentation in the elderly and demented residents of nursing homes. Bull. Clin. Neurosci. 1989, 127-132.
2. Ancoli-Israel S., Gehrman P., Martin J.L., Shochat T., Marler M., Corey-Bloom J., Levi L. Increased light exposure consolidates sleep and strengthens circadian rhythms in severe Alzheimer's disease patients. Behav. Sleep Med. 2003, 1:22-36.
3. Arrieta-Cruz I., Pfaff D.W. Definition of arousal and mechanistic studies in intact and brain-damaged mice. Ann. N. Y. Acad. Sci. 2009, 1157:24-31.
4. Bachman D., Rabins P. "Sundowning" and other temporally associated agitation states in dementia patients. Annu. Rev. Med. 2006, 57:499-511.
5. Barak S., Weiner I. Scopolamine induces disruption of latent inhibition which is prevented by antipsychotic drugs and an acetylcholinesterase inhibitor. Neuropsychopharmacology 2007, 32:989-999.
6. Bedrosian T.A., Fonken L.K., Walton J.C., Haim A., Nelson R.J. Dim light at night provokes depression-like behaviors and reduces CA1 dendritic spine density in female hamsters. Psychoneuroendocrinology 2011, 36:1062-1069.
7. Bedrosian T.A., Herring K.L., Weil Z.M., Nelson R.J. Altered temporal patterns of anxiety in aged and amyloid precursor protein (APP) transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:11686-11691.
8. Benca R., Duncan M.J., Frank E., McClung C., Nelson R.J., Vicentic A. Biological rhythms, higher brain function, and behavior: gaps, opportunities, and challenges. Brain Res. Rev. 2009, 62:57-70.
9. Bliwise D.L., Carroll J.S., Lee K.A., Nekich J.C., Dement W.C. Sleep and "sundowning" in nursing home patients with dementia. Psychiatry Res. 1993, 48:277-292.
10. Bliwise D.L., Hughes M., McMahon P.M., Kutner N. Observed sleep/wakefulness and severity of dementia in an Alzheimer's disease special care unit. J. Gerontol. A Biol. Sci. Med. Sci. 1995, 50:M303-M306.
11. Bliwise D.L., Mercaldo N.D., Avidan A.Y., Boeve B.F., Greer S.A., Kukull W.A. Sleep disturbance in dementia with Lewy bodies and Alzheimer's disease: a multicenter analysis. Dement. Geriatr. Cogn. Disord. 2011, 31:239-246.
12. Boivin D.B., Duffy J.F., Kronauer R.E., Czeisler C.A. Dose-response relationships for resetting of human circadian clock by light. Nature 1996, 379:540-542.
13. Brioni J.D., O'Neill A.B., Kim D.J., Decker M.W. Nicotinic receptor agonists exhibit anxiolytic-like effects on the elevated plus-maze test. Eur. J. Pharmacol. 1993, 238:1-8.
14. Burgio L.D., Scilley K., Hardin J.M., Janosky J., Bonino P., Slater S.C., Engberg R. Studying disruptive vocalization and contextual factors in the nursing home using computer-assisted real-time observation. J. Gerontol. 1994, 49:P230-P239.
15. Burgio L.D., Scilley K., Hardin J.M., Hsu C. Temporal patterns of disruptive vocalization in elderly nursing home residents. Int. J. Geriatr. Psychiatry 2001, 16:378-386.
16. Cameron D. Studies in senile nocturnal delirium. Psychiatr. Q. 1941, 15:47-53.
17. Cardinali D.P., Furio A.M., Brusco L.I. Clinical aspects of melatonin intervention in Alzheimer's disease progression. Curr. Neuropharmacol. 2010, 8:218-227.
18. Charman W.N. Age, lens transmittance, and the possible effects of light on melatonin suppression. Ophthalmic. Physiol. Opt. 2003, 23:181-187.
19. Coen R.F., Swanwick G.R., O'Boyle C.A., Coakley D. Behaviour disturbance and other predictors of carer burden in Alzheimer's disease. Int. J. Geriatr. Psychiatry 1997, 12:331-336.
20. Cohen-Mansfield J. Temporal patterns of agitation in dementia. Am. J. Geriatr. Psychiatry 2007, 15:395-405.
21. Cohen-Mansfield J., Garfinkel D., Lipson S. Melatonin for treatment of sundowning in elderly persons with dementia - a preliminary study. Arch. Gerontol. Geriatr. 2000, 31:65-76.
22. de Jonghe A., Korevaar J.C., van Munster B.C., de Rooij S.E. Effectiveness of melatonin treatment on circadian rhythm disturbances in dementia. Are there implications for delirium? A systematic review. Int. J. Geriatr. Psychiatry 2010, 25:1201-1208.
23. Donaldson C., Tarrier N., Burns A. Determinants of carer stress in Alzheimer's disease. Int. J. Geriatr. Psychiatry 1998, 13:248-256.
24. Evans L.K. Sundown syndrome in institutionalized elderly. J. Am. Geriatr. Soc. 1987, 35:101-108.
25. Finkel S. Introduction to behavioural and psychological symptoms of dementia (BPSD). Int. J. Geriatr. Psychiatry 2000, 15(Suppl. 1):S2-S4.
26. Foley D.J., Monjan A.A., Brown S.L., Simonsick E.M., Wallace R.B., Blazer D.G. Sleep complaints among elderly persons: an epidemiologic study of three communities. Sleep 1995, 18:425-432.
27. Forbes D., Culum I., Lischka A.R., Morgan D.G., Peacock S., Forbes J., Forbes S. Light therapy for managing cognitive, sleep, functional, behavioural, or psychiatric disturbances in dementia. Cochrane Database Syst. Rev. 2009, CD003946.
28. Gallagher-Thompson D., Brooks J.O., Bliwise D., Leader J., Yesavage J.A. The relations among caregiver stress, "sundowning" symptoms, and cognitive decline in Alzheimer's disease. J. Am. Geriatr. Soc. 1992, 40:807-810.
29. Godfrey A., Leonard M., Donnelly S., Conroy M., Olaighin G., Meagher D. Validating a new clinical subtyping scheme for delirium with electronic motion analysis. Psychiatry Res. 2010, 178:186-190.
30. Greve M., O'Connor D. A survey of Australian and New Zealand old age psychiatrists' preferred medications to treat behavioral and psychological symptoms of dementia (BPSD). Int. Psychogeriatr. 2005, 17:195-205.
31. Hatfield C.F., Herbert J., van Someren E.J., Hodges J.R., Hastings M.H. Disrupted daily activity/rest cycles in relation to daily cortisol rhythms of home-dwelling patients with early Alzheimer's dementia. Brain 2004, 127:1061-1074.
32. Hattar S., Lucas R.J., Mrosovsky N., Thompson S., Douglas R.H., Hankins M.W., Lem J., Biel M., Hofmann F., Foster R.G., Yau K.W. Melanopsin and rod-cone photoreceptive systems account for all major accessory visual functions in mice. Nature 2003, 424:76-81.
33. Herrmann N., Lanctot K.L., Sambrook R., Lesnikova N., Hebert R., McCracken P., Robillard A., Nguyen E. The contribution of neuropsychiatric symptoms to the cost of dementia care. Int. J. Geriatr. Psychiatry 2006, 21:972-976.
34. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
35. Huitron-Resendiz S., Sanchez-Alavez M., Gallegos R., Berg G., Crawford E., Giacchino J.L., Games D., Henriksen S.J., Criado J.R. Age-independent and age-related deficits in visuospatial learning, sleep-wake states, thermoregulation and motor activity in PDAPP mice. Brain Res. 2002, 928:126-137.
36. Irvine E.E., Cheeta S., File S.E. Time-course of changes in the social interaction test of anxiety following acute and chronic administration of nicotine. Behav. Pharmacol. 1999, 10:691-697.
37. Kahn-Greene E.T., Killgore D.B., Kamimori G.H., Balkin T.J., Killgore W.D. The effects of sleep deprivation on symptoms of psychopathology in healthy adults. Sleep Med. 2007, 8:215-221.
38. Khachiyants N., Trinkle D., Son S.J., Kim K.Y. Sundown syndrome in persons with dementia: an update. Psychiatry Investig. 2011, 8:275-287.
39. Kim P., Louis C., Muralee S., Tampi R. Sundowning syndrome in the older patient. Clin. Geriatr. 2005, 13:32-36.
40. Klaffke S., Staedt J. Sundowning and circadian rhythm disorders in dementia. Acta Neurol. Belg. 2006, 106:168-175.
41. Lebert F., Pasquier F., Petit H. Sundowning syndrome in demented patients without neuroleptic therapy. Arch. Gerontol. Geriatr. 1996, 22:49-54.
42. Madeira M.D., Pereira P.A., Silva S.M., Cadete-Leite A., Paula-Barbosa M.M. Basal forebrain neurons modulate the synthesis and expression of neuropeptides in the rat suprachiasmatic nucleus. Neuroscience 2004, 125:889-901.
43. Mahlberg R., Kunz D., Sutej I., Kuhl K.P., Hellweg R. Melatonin treatment of day-night rhythm disturbances and sundowning in Alzheimer disease: an open-label pilot study using actigraphy. J. Clin. Psychopharmacol. 2004, 24:456-459.
44. Mahoney R., Regan C., Katona C., Livingston G. Anxiety and depression in family caregivers of people with Alzheimer disease: the LASER-AD study. Am. J. Geriatr. Psychiatry 2005, 13:795-801.
45. Martin J., Marler M., Shochat T., Ancoli-Israel S. Circadian rhythms of agitation in institutionalized patients with Alzheimer's disease. Chronobiol. Int. 2000, 17:405-418.
46. McGeer P.L., McGeer E.G., Suzuki J., Dolman C.E., Nagai T. Aging, Alzheimer's disease, and the cholinergic system of the basal forebrain. Neurology 1984, 34:741-745.
47. Nakamura K., Kurasawa M., Tanaka Y. Scopolamine model of delirium in rats and reversal of the performance impairment by aniracetam. Drug Dev. Res. 2008, 43:85-97.
48. Nakamura T.J., Nakamura W., Yamazaki S., Kudo T., Cutler T., Colwell C.S., Block G.D. Age-related decline in circadian output. J. Neurosci. 2011, 31:10201-10205.
49. Nowak L., Davis J.E. A qualitative examination of the phenomenon of sundowning. J. Nurs. Scholarsh. 2007, 39:256-258.
50. Pollak C.P., Perlick D. Sleep problems and institutionalization of the elderly. J. Geriatr. Psychiatry Neurol. 1991, 4:204-210.
51. Pollak C.P., Perlick D., Linsner J.P., Wenston J., Hsieh F. Sleep problems in the community elderly as predictors of death and nursing home placement. J. Community Health 1990, 15:123-135.
52. Rodgers R.J., Cole J.C. Effects of scopolamine and its quaternary analogue in the murine elevated plus-maze test of anxiety. Behav. Pharmacol. 1995, 6:283-289.
53. Rothman S.M., Herdener N., Camandola S., Texel S.J., Mughal M.R., Cong W.N., Martin B., Mattson M.P. 3×TgAD mice exhibit altered behavior and elevated Abeta after chronic mild social stress. Neurobiol. Aging 2012, 33(4):830.e1-830.e12.
54. Sasahara M., Fries J.W., Raines E.W., Gown A.M., Westrum L.E., Frosch M.P., Bonthron D.T., Ross R., Collins T. PDGF B-chain in neurons of the central nervous system, posterior pituitary, and in a transgenic model. Cell 1991, 64:217-227.
55. Satlin A., Volicer L., Ross V., Herz L., Campbell S. Bright light treatment of behavioral and sleep disturbances in patients with Alzheimer's disease. Am. J. Psychiatry 1992, 149:1028-1032.
56. Scheuermaier K., Laffan A.M., Duffy J.F. Light exposure patterns in healthy older and young adults. J. Biol. Rhythms 2010, 25:113-122.
57. Schneider L.S., Dagerman K.S., Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005, 294:1934-1943.
58. Shochat T., Martin J., Marler M., Ancoli-Israel S. Illumination levels in nursing home patients: effects on sleep and activity rhythms. J. Sleep Res. 2000, 9:373-379.
59. Sienkiewicz-Jarosz H., Czlonkowska A.I., Siemiatkowski M., Maciejak P., Szyndler J., Plaznik A. The effects of physostigmine and cholinergic receptor ligands on novelty-induced neophobia. J. Neural. Transm. 2000, 107:1403-1412.
60. Silva R.H., Kameda S.R., Carvalho R.C., Takatsu-Coleman A.L., Niigaki S.T., Abilio V.C., Tufik S., Frussa-Filho R. Anxiogenic effect of sleep deprivation in the elevated plus-maze test in mice. Psychopharmacology (Berl) 2004, 176:115-122.
61. Skene D.J., Swaab D.F. Melatonin rhythmicity: effect of age and Alzheimer's disease. Exp. Gerontol. 2003, 38:199-206.
62. Skjerve A., Nygaard H.A. Improvement in sundowning in dementia with Lewy bodies after treatment with donepezil. Int. J. Geriatr. Psychiatry 2000, 15:1147-1151.
63. Smythe J.W., Murphy D., Bhatnagar S., Timothy C., Costall B. Muscarinic antagonists are anxiogenic in rats tested in the black-white box. Pharmacol. Biochem. Behav. 1996, 54:57-63.
64. Staedt J., Stoppe G. Treatment of rest-activity disorders in dementia and special focus on sundowning. Int. J. Geriatr. Psychiatry 2005, 20:507-511.
65. Stoppe G., Brandt C.A., Staedt J.H. Behavioural problems associated with dementia: the role of newer antipsychotics. Drugs Aging 1999, 14:41-54.
66. Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K.H., Mistl C., Rothacher S., Ledermann B., Burki K., Frey P., Paganetti P.A., Waridel C., Calhoun M.E., Jucker M., Probst A., Staufenbiel M., Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:13287-13292.
67. Szyndler J., Sienkiewicz-Jarosz H., Maciejak P., Siemiatkowski M., Rokicki D., Czlonkowska A.I., Plaznik A. The anxiolytic-like effect of nicotine undergoes rapid tolerance in a model of contextual fear conditioning in rats. Pharmacol. Biochem. Behav. 2001, 69:511-518.
68. Tractenberg R.E., Singer C.M., Cummings J.L., Thal L.J. The Sleep Disorders Inventory: an instrument for studies of sleep disturbance in persons with Alzheimer's disease. J. Sleep Res. 2003, 12:331-337.
69. Trinh N.H., Hoblyn J., Mohanty S., Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 2003, 289:210-216.
70. Van Someren E.J. Circadian and sleep disturbances in the elderly. Exp. Gerontol. 2000, 35:1229-1237.
71. Vandekerckhove M., Cluydts R. The emotional brain and sleep: an intimate relationship. Sleep Med. Rev. 2010, 14:219-226.
72. Vitiello M.V., Borson S. Sleep disturbances in patients with Alzheimer's disease: epidemiology, pathophysiology and treatment. CNS Drugs 2001, 15:777-796.
73. Vloeberghs E., Van Dam D., Engelborghs S., Nagels G., Staufenbiel M., De Deyn P.P. Altered circadian locomotor activity in APP23 mice: a model for BPSD disturbances. Eur. J. Neurosci. 2004, 20:2757-2766.
74. Volicer L., Harper D.G., Manning B.C., Goldstein R., Satlin A. Sundowning and circadian rhythms in Alzheimer's disease. Am. J. Psychiatry 2001, 158:704-711.
75. Wenk G.L. The nucleus basalis magnocellularis cholinergic system: one hundred years of progress. Neurobiol. Learn. Mem. 1997, 67:85-95.
76. Workman J.L., Nelson R.J. Potential animal models of seasonal affective disorder. Neurosci. Biobehav. Rev. 2010, 35:669-679.
77. Wu Y.H., Swaab D.F. The human pineal gland and melatonin in aging and Alzheimer's disease. J. Pineal Res. 2005, 38:145-152.
78. Yuen E.J., Zisselman M.H., Louis D.Z., Rovner B.W. Sedative-hypnotic use by the elderly: effects on hospital length of stay and costs. J. Ment. Health Adm. 1997, 24:90-97.
79. Zohar D., Tzischinsky O., Epstein R., Lavie P. The effects of sleep loss on medical residents' emotional reactions to work events: a cognitive-energy model. Sleep 2005, 28:47-54.